Compare NBN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | PCRX |
|---|---|---|
| Founded | 1872 | 2006 |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | NBN | PCRX |
|---|---|---|
| Price | $125.85 | $23.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $130.50 | $30.25 |
| AVG Volume (30 Days) | 98.8K | ★ 517.6K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.03% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $13.77 | $6.78 |
| Revenue Next Year | $18.72 | $8.54 |
| P/E Ratio | ★ $11.29 | $338.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $79.26 | $18.80 |
| 52 Week High | $135.62 | $27.64 |
| Indicator | NBN | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 49.35 |
| Support Level | $115.99 | $22.06 |
| Resistance Level | $135.62 | $24.20 |
| Average True Range (ATR) | 3.75 | 1.04 |
| MACD | 0.33 | 0.06 |
| Stochastic Oscillator | 83.29 | 49.23 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.